Genentech will collaborate with Nvidia to build what will be a next-generation artificial intelligence (AI) platform for drug discovery, according to a press release.

”By harnessing the power of AI models and algorithms together with our unique data and experiments, we can make scientific discoveries at an incredible speed and generate insights at an unprecedented scale,” said Aviv Regev, Head of Research and Early Development at Genentech.

The companies will accelerate and optimize Genentech’s proprietary machine learning algorithms and models on NVIDIA DGX Cloud, which is built on NVIDIA’s AI supercomputing and software, including NVIDIA BioNemo for generative AI applications in drug discovery.

The collaboration will also help accelerate Genentech’s ”lab in a loop,” where extensive experimental data feeds computational models that reveal patterns and create new experimentally testable predictions.

Researchers will then evaluate the predictions in the lab, and the results will be fed back into the models to improve the underlying computational model, enabling the development of better therapies, according to the press release.